Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals-Reference-Cited by-同舟云学术

Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals

Published:2005-02 Issue:1 Volume:100 Page:85-89
ISSN:0074-0276
Container-title:Memórias do Instituto Oswaldo Cruz
language:
Short-container-title:Mem. Inst. Oswaldo Cruz

Author:

Bongertz V¹,Teixeira SLM¹,Grinztejn B²,Pilotto JH²,Veloso VG²,Morgado MG¹,Bastos FI³,Ouverney EP¹

Affiliation:

1. Instituto Oswaldo Cruz-Fiocruz, Brasil

2. Instituto de Pesquisa Evandro Chagas-Fiocruz

3. Centro de Informações Científicas e Tecnológicas-Fiocruz, Brazil

Publisher

FapUNIFESP (SciELO)

Subject

Microbiology (medical)

Link

http://www.scielo.br/pdf/mioc/v100n1/v100n1a16.pdf

Reference37 articles.

1. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection;Baba TW;Nat Med,2000

2. Vertical HIV-1 transmission: importance of neutralizing antibody titer and specificity;Bongertz V;Scand J Immunol,2001

3. Neutralization titers and Vertical HIV-1 transmission;Bongertz V;Scand J Immunol,2002

4. Anti-HIV-1 seroreactivity in distinct transmission risk groups;Bongertz V;J Clin Virol,1999

5. The Brazilian Network for HIV Isolation and Characterization 2003: Higher anti-HIV-1 antibody titers in injection drug users compared to sexually infected individuals;Bongertz V;Mem Inst Oswaldo Cruz

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short Communication: Neutralizing Antibodies in HIV-1-Infected Brazilian Individuals;AIDS Research and Human Retroviruses;2013-03

2. Higher cross-subtype IFN-γ ELISpot responses to Gag and Nef peptides in Brazilian HIV-1 subtype B- and F1- than in C-infected subjects;Vaccine;2013-02

3. HIV Type 1 Genetic Variability in Central Brazil;AIDS Research and Human Retroviruses;2007-12

4. Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment;Memórias do Instituto Oswaldo Cruz;2007-08-31